• Olema Pharmaceuticals OLMA shares, a clinical-stage biopharmaceutical firm, rose 1.8% to $13.2.
Olema states that its clinical partnership and supply arrangement with Novartis NOVN of Switzerland has expanded.
  •  The revised agreement to expand a current early-to-mid-stage trial's scope
  • The study is evaluating the combination of the anti-cancer medication ribociclib from Novartis and the main drug candidate from OLMA, palazestrant, to treat a specific kind of breast cancer.
  • Olema and NOVN first agreed to a clinical partnership and supply agreement in July 2020; it was revised and reaffirmed in January 2022.
YTD, stock is risen roughly 438%.

Disclaimer: We don,t provide any Investment advice.